What is the ticker symbol for Merus N.V.?

Merus N.V. trades under the ticker MRUS on NASDAQ.

What sector does Merus N.V. operate in?

Merus N.V. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MRUS in a portfolio?

PortView shows MRUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Merus N.V. (MRUS) Stock Analysis

NASDAQHealthcareBiotechnology

$90.00+0.00%

1-year price historyRange $34.89 – $97.01

52-week range$90.00

$33.19$97.14

What Merus N.V. does

Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.

Key metrics

Market cap

$6.83B

P/E (TTM)

-17.05

EPS (TTM)

$-5.28

Beta

1.06

Dividend yield

0.00%

Revenue / share

$0.58

50-day avg

$95.61

200-day avg

$68.01

52-week high

$97.14

52-week low

$33.19

CEO

Jan van de Winkel

ETFs linked to MRUS

Broad-market and Healthcare sector ETFs an investor holding Merus N.V. is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how MRUS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze MRUS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Merus N.V.?: Merus N.V. trades under the ticker MRUS on NASDAQ.
Which exchange is MRUS listed on?: MRUS is listed on NASDAQ.
What sector does Merus N.V. operate in?: Merus N.V. is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze MRUS in a portfolio?: PortView shows MRUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.